Trial · NCT02606305
Participant flow180
How many started, completed or left each group, period by period.
41 to 60 of 180
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Dose Escalation: Regimens A, B, C and D | COMPLETED | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | 7 | |
| Dose Escalation: Regimens A, B, C and D | COMPLETED | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | 4 | |
| Dose Escalation: Regimens A, B, C and D | COMPLETED | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | 10 | |
| Dose Escalation: Regimens A, B, C and D | COMPLETED | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | 0 | |
| Dose Escalation: Regimens A, B, C and D | COMPLETED | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen A Dose Expansion Cohort 1: Bevacizumab-naïve | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen A Dose Expansion Cohort 2: Bevacizumab Pre-treated | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen A Dose Expansion Cohort 3: Pt-agnostic: | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | 0 | |
| Dose Escalation: Regimens A, B, C and D | NOT COMPLETED | Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02606305/flow?page=3